亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High–risk Pulmonary Embolism

医学 肺栓塞 溶栓 内科学 外科 心脏病学 心肌梗塞
作者
Parham Sadeghipour,Yaser Jenab,Jamal Moosavi,Kaveh Hosseini,Bahram Mohebbi,Ali Hosseinsabet,Saurav Chatterjee,Hamidreza Pouraliakbar,Shapour Shirani,Mehdi H. Shishehbor,Azin Alizadehasl,Melody Farrashi,Mohammad Ali Rezvani,Farnaz Rafiee,Arash Jalali,Sina Rashedi,Omid Shafe,Jay Giri,Manuel Monréal,David Jiménez
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:7 (12): 1189-1189 被引量:116
标识
DOI:10.1001/jamacardio.2022.3591
摘要

Importance: The optimal treatment of intermediate-high-risk pulmonary embolism (PE) remains unknown. Objective: To assess the effect of conventional catheter-directed thrombolysis (cCDT) plus anticoagulation vs anticoagulation monotherapy in improving echocardiographic measures of right ventricle (RV) to left ventricle (LV) ratio in acute intermediate-high-risk PE. Design, Setting, and Participants: The Catheter-Directed Thrombolysis vs Anticoagulation in Patients with Acute Intermediate-High-Risk Pulmonary Embolism (CANARY) trial was an open-label, randomized clinical trial of patients with intermediate-high-risk PE, conducted in 2 large cardiovascular centers in Tehran, Iran, between December 22, 2018, through February 2, 2020. Interventions: Patients were randomly assigned to cCDT (alteplase, 0.5 mg/catheter/h for 24 hours) plus heparin vs anticoagulation monotherapy. Main Outcomes and Measures: The proportion of patients with a 3-month echocardiographic RV/LV ratio greater than 0.9, assessed by a core laboratory, was the primary outcome. The proportion of patients with an RV/LV ratio greater than 0.9 at 72 hours after randomization and the 3-month all-cause mortality were among secondary outcomes. Major bleeding (Bleeding Academic Research Consortium type 3 or 5) was the main safety outcome. A clinical events committee, masked to the treatment assignment, adjudicated clinical outcomes. Results: The study was prematurely stopped due to the COVID-19 pandemic after recruiting 94 patients (mean [SD] age, 58.4 [2.5] years; 27 women [29%]), of whom 85 patients completed the 3-month echocardiographic follow-up. Overall, 2 of 46 patients (4.3%) in the cCDT group and 5 of 39 patients (12.8%) in the anticoagulation monotherapy group met the primary outcome (odds ratio [OR], 0.31; 95% CI, 0.06-1.69; P = .24). The median (IQR) 3-month RV/LV ratio was significantly lower with cCDT (0.7 [0.6-0.7]) than with anticoagulation (0.8 [0.7-0.9); P = .01). An RV/LV ratio greater than 0.9 at 72 hours after randomization was observed in fewer patients treated with cCDT (13 of 48 [27.0%]) than anticoagulation (24 of 46 [52.1%]; OR, 0.34; 95% CI, 0.14-0.80; P = .01). Fewer patients assigned to cCDT experienced a 3-month composite of death or RV/LV greater than 0.9 (2 of 48 [4.3%] vs 8 of 46 [17.3%]; OR, 0.20; 95% CI, 0.04-1.03; P = .048). One case of nonfatal major gastrointestinal bleeding occurred in the cCDT group. Conclusions and Relevance: This prematurely terminated randomized clinical trial of patients with intermediate-high-risk PE was hypothesis-generating for improvement in some efficacy outcomes and acceptable rate of major bleeding for cCDT compared with anticoagulation monotherapy and provided support for a definitive clinical outcomes trial. Trial Registration: ClinicalTrials.gov Identifier: NCT05172115.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
开朗的雪瑶完成签到,获得积分10
3秒前
5秒前
spolo完成签到,获得积分10
23秒前
坦率的天玉完成签到,获得积分10
28秒前
28秒前
Maestro_S的应助被PennPeak采纳,获得10
32秒前
36秒前
Xee完成签到,获得积分10
41秒前
磊4165564发布了新的文献求助10
42秒前
王智慧完成签到 ,获得积分10
49秒前
大模型的应助被科研通管家采纳,获得10
51秒前
Owen的应助被科研通管家采纳,获得10
51秒前
51秒前
lazyp完成签到 ,获得积分10
52秒前
大胆蛟凤完成签到,获得积分10
54秒前
gx发布了新的文献求助10
55秒前
56秒前
59秒前
激情的菲音完成签到,获得积分10
1分钟前
gx发布了新的文献求助10
1分钟前
642463016发布了新的文献求助50
1分钟前
1分钟前
Heaven完成签到,获得积分10
1分钟前
Heaven发布了新的文献求助10
1分钟前
1分钟前
1分钟前
Benhnhk21完成签到,获得积分10
1分钟前
zilicai发布了新的文献求助10
1分钟前
1分钟前
万能图书馆的应助被17712570999采纳,获得10
1分钟前
1分钟前
qqq完成签到,获得积分10
1分钟前
独特幻丝发布了新的文献求助10
1分钟前
开心的灭龙完成签到,获得积分10
2分钟前
kiki0808完成签到 ,获得积分10
2分钟前
彩色的勒完成签到,获得积分10
2分钟前
2分钟前
2分钟前
17712570999发布了新的文献求助10
2分钟前
风吹麦浪的应助被苏景烟采纳,获得20
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179810
求助须知:如何正确求助?哪些是违规求助? 9570029
关于积分的说明 21808087
捐赠科研通 7775456
什么是DOI,文献DOI怎么找? 3433157
关于科研通互助平台的介绍 2557233
邀请新用户注册赠送积分活动 2478832